AVTX · Categories · Offerings
AVTX - Public offerings
Avalo Therapeutics Inc. (AVTX) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for AVTX
- Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesAchieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.
- Avalo Therapeutics Announces Pricing of $375 Million Public OfferingWAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of
- Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsWAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Avalo. In addition, Avalo intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its com
- Avalo Reports 2022 Financial Results and Provides Business UpdatesCompleted enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023Disclosed cash of approximately $13 million as of December 31, 2022, non-inclusive of the February 2023 public offeringIncreased cash position with closing of public offering of common stock and warrants for gross proceeds of $15 million on February 7, 2023 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced business updates and year-end financial results for 2022. "We made significant strategic and operational progress over the past year, by executing our goals of streamlining
- Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and WarrantsWAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a price to the public of $3.98 per share and warrant. The warrants have a one-year term and an exercise price of $5.00 per share. The offering is expected to close on February 7, 2023, subject to customary closing conditions. The gross proceeds to Avalo from the public offering, before deducting underwriting discounts and commissions and offering expenses payable by Avalo, are expected to be a
- Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and WarrantsWAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo") announced today that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the shares and warrants in the proposed offering are to be sold by Avalo. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Securities and RBC Capital Markets are acting as joint bookrunning managers for the offering. The offering is being made pursuant to a shelf regist
- Avalo Appoints Two New Independent Directors to Its BoardWAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases today announced the appointment of Dr. June Almenoff, effective November 10, 2021, and Mitchell Chan, effective December 1, 2021 as independent members of its Board of Directors. These two new independent directors are replacing Dr. Suzanne Bruhn and Philip Gutry. "We are pleased to welcome both Dr. Almenoff and Mr. Chan to our Board. Their collective experience
- Avalo Reports Third Quarter 2021 Financial Results and Provides Business UpdatesTopline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021Multiple data readouts across programs anticipated within the next six monthsCash and cash equivalents of $71.5 million on hand following recent financing transactions during the quarter WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases today announced business updates and third quarter 2021 fi
- Avalo to Present at the 2021 Cantor Virtual Global Healthcare ConferenceWAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that members of its senior management team will present in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference being held from September 27th through September 30th, 2021. 2021 Cantor Virtual Global Healthcare ConferenceDate: Wednesday, September 29th, 2021Time: 2:00 PM ET A live webcast of the fireside chat can be accessed u
- Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common StockWAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. ("Avalo" or the "Company") (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases, announced today that it has entered into an underwriting agreement with Jefferies LLC and RBC Capital Markets, LLC under which the underwriters agreed to purchase, on a firm commitment basis, 12,500,000 shares of common stock of the Company, at a public offering price of $2.20 per share (the "Public Offering Price"). The offering is ex
- Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common StockWAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. ("Avalo" or the "Company") (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases, announced today that it intends to offer for sale shares of its common stock in an underwritten public offering. Avalo intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the proposed offering of up to 15% of the aggregate number of shares of common stock. All of the shares of com